Cervical Cancer: Understanding Prevention, Diagnosis, and Global Efforts to Eliminate It

Key Statistics

Cervical cancer represents the fifth most frequently diagnosed cancer among women worldwide, with an estimated 604,000 new cases and nearly 280,000 deaths projected for 2024. The burden remains heaviest in low- and middle-income countries, where limited access to vital health services exacerbates health disparities.

Overview of Cervical Cancer

This cancer is the leading cause of cancer-related deaths among women in 26 nations, particularly in sub-Saharan Africa, parts of Central and South America, Melanesia, and Southeast Asia. These disparities arise from inequitable access to HPV vaccinations, screening methods, and necessary treatment options. Risk factors such as the prevalence of HIV and socio-economic conditions—like gender inequality and poverty—also significantly impact cancer rates.

Women living with HIV have a sixfold increased risk of developing cervical cancer compared to their HIV-negative counterparts, with HIV accounting for roughly 5% of cervical cancer cases. Furthermore, younger women are disproportionately affected, leading to substantial maternal loss due to this disease.

Understanding the Causes

The vast majority of cervical cancer cases originate from persistent infections with specific oncogenic strains of the human papillomavirus (HPV), which is a prevalent sexually transmitted infection. Most sexually active individuals will encounter HPV at some point, often without displaying symptoms. While the immune system typically clears the virus naturally, some HPV types can lead to abnormal cell growth that transforms into cancer over time. It can take between 15 to 20 years for these changes to manifest as cancer—an accelerated progression may occur in women with weakened immune systems.

Prevention Strategies

Effective prevention hinges on enhancing public awareness, understanding of health systems, and accessibility to information and services. Key preventive measures include:

• HPV Vaccination: Administered to girls aged 9 to 14, the HPV vaccine is highly effective in preventing cervical cancer and other HPV-linked malignancies.
• Cervical Screening: Recommendations advise women to begin screenings at age 30 (or 25 for women living with HIV) to identify precursors to cervical cancer.
• Early Diagnosis and Treatment: Prompt medical consultation upon experiencing symptoms like unusual bleeding or pelvic pain can lead to successful treatment of cervical cancer.

HPV Vaccination

As of 2025, a total of eight HPV vaccines are licensed, with five achieving WHO pre-qualification for global distribution. It is imperative that girls receive the vaccine before any potential viral exposure, with the option of one or two doses dependent on national vaccination schedules. Special consideration is given to individuals with compromised immune systems, including those with HIV, who should ideally receive additional doses.

Cervical Screening Protocols

Women should undergo cervical cancer screening every five to ten years starting from age 30, with increased frequency recommended for those living with HIV. The global health strategy aims for women to have at least two screenings during their lifetime by specific age benchmarks. Notably, self-collection methods for HPV testing have proven to be as effective as clinician-collected samples.

Diagnosing and Treating Cervical Cancer

Early-stage cervical cancer can often be treated successfully. Symptoms of concern include:

• Unexplained bleeding, particularly post-menopause or after sexual intercourse
• Increased vaginal discharge with a foul odor
• Persistent pain in lower back or pelvic areas
• Significant weight loss or fatigue
• Unusual swelling in the legs

Diagnostic procedures typically follow symptom assessment. Treatment modalities may include surgery, chemotherapy, and radiotherapy, alongside palliative care to enhance the quality of life.

Global Response and Elimination Efforts

The WHO has set a global commitment to eliminate cervical cancer as a public health concern by targeting a reduction to under four cases per 100,000 women annually. To achieve this, specific goals by 2030 include:

• 90% of girls fully vaccinated with the HPV vaccine by age 15
• 70% of women screened appropriately by ages 35 and 45
• 90% of women diagnosed with cervical precancer or cancer receiving necessary treatment

These initiatives could potentially prevent millions of new cervical cancer cases and save countless lives, particularly among women living with HIV.

World Cervical Cancer Elimination Day

November 17 marks World Cervical Cancer Elimination Day, a call to action aimed at enhancing global efforts in vaccination, screening, and treatment services for cervical cancer. Key stakeholders are encouraged to collaborate and make progress in addressing this significant health issue.

References

Ferlay J EM, Lam F, Laversanne M, Colombet M, Mery L et al. . Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2026.
Stelze, Dominik et al. Estimates of the global burden of cervical cancer associated with HIV. The Lancet. 2020.
Kidman, R., Ferlay, J. et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med 28, 2563–2572 (2022).